Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 247

1.

Immunosuppressive human anti-CD83 monoclonal antibody depletion of activated dendritic cells in transplantation.

Seldon TA, Pryor R, Palkova A, Jones ML, Verma ND, Findova M, Braet K, Sheng Y, Fan Y, Zhou YY, Marks JD, Munro T, Mahler SM, Barnard RT, Fromm PD, Silveira PA, Elgundi Z, Ju X, Clark GJ, Bradstock KF, Munster DJ, Hart DN.

Leukemia. 2015 Aug 19. doi: 10.1038/leu.2015.231. [Epub ahead of print]

PMID:
26286117
2.

Monoclonal Antibodies Targeting the Alpha-Exosite of Botulinum Neurotoxin Serotype/A Inhibit Catalytic Activity.

Fan Y, Geren IN, Dong J, Lou J, Wen W, Conrad F, Smith TJ, Smith LA, Ho M, Pires-Alves M, Wilson BA, Marks JD.

PLoS One. 2015 Aug 14;10(8):e0135306. doi: 10.1371/journal.pone.0135306. eCollection 2015.

3.

TGF-β-Dependent Dendritic Cell Chemokinesis in Murine Models of Airway Disease.

Hashimoto M, Yanagisawa H, Minagawa S, Sen D, Ma R, Murray LA, Tsui P, Lou J, Marks JD, Baron JL, Krummel MF, Nishimura SL.

J Immunol. 2015 Aug 1;195(3):1182-90. doi: 10.4049/jimmunol.1500348. Epub 2015 Jun 24.

PMID:
26109638
4.

A fully human scFv phage display library for rapid antibody fragment reformatting.

Li K, Zettlitz KA, Lipianskaya J, Zhou Y, Marks JD, Mallick P, Reiter RE, Wu AM.

Protein Eng Des Sel. 2015 May 19. pii: gzv024. [Epub ahead of print]

PMID:
25991864
5.

Transforming Growth Factor-β and Interleukin-1β Signaling Pathways Converge on the Chemokine CCL20 Promoter.

Brand OJ, Somanath S, Moermans C, Yanagisawa H, Hashimoto M, Cambier S, Markovics J, Bondesson AJ, Hill A, Jablons D, Wolters P, Lou J, Marks JD, Baron JL, Nishimura SL.

J Biol Chem. 2015 Jun 5;290(23):14717-28. doi: 10.1074/jbc.M114.630368. Epub 2015 Apr 27.

PMID:
25918170
6.

Combining anti-ERBB3 antibodies specific for domain I and domain III enhances the anti-tumor activity over the individual monoclonal antibodies.

D'Souza JW, Reddy S, Goldsmith LE, Shchaveleva I, Marks JD, Litwin S, Robinson MK.

PLoS One. 2014 Nov 11;9(11):e112376. doi: 10.1371/journal.pone.0112376. eCollection 2014.

7.

High throughput identification of monoclonal antibodies to membrane bound and secreted proteins using yeast and phage display.

Zhao L, Qu L, Zhou J, Sun Z, Zou H, Chen YY, Marks JD, Zhou Y.

PLoS One. 2014 Oct 29;9(10):e111339. doi: 10.1371/journal.pone.0111339. eCollection 2014.

8.
9.

Anti-MET immunoPET for non-small cell lung cancer using novel fully human antibody fragments.

Li K, Tavaré R, Zettlitz KA, Mumenthaler SM, Mallick P, Zhou Y, Marks JD, Wu AM.

Mol Cancer Ther. 2014 Nov;13(11):2607-17. doi: 10.1158/1535-7163.MCT-14-0363. Epub 2014 Aug 20.

PMID:
25143449
10.

Development of an ELISA microarray assay for the sensitive and simultaneous detection of ten biodefense toxins.

Jenko KL, Zhang Y, Kostenko Y, Fan Y, Garcia-Rodriguez C, Lou J, Marks JD, Varnum SM.

Analyst. 2014 Oct 21;139(20):5093-102. doi: 10.1039/c4an01270d. Epub 2014 Aug 12.

PMID:
25112421
11.

Enhanced immunoPET of ALCAM-positive colorectal carcinoma using site-specific ⁶⁴Cu-DOTA conjugation.

Tavaré R, Wu WH, Zettlitz KA, Salazar FB, McCabe KE, Marks JD, Wu AM.

Protein Eng Des Sel. 2014 Oct;27(10):317-24. doi: 10.1093/protein/gzu030. Epub 2014 Aug 4.

PMID:
25095796
12.

Selective targeting of TGF-β activation to treat fibroinflammatory airway disease.

Minagawa S, Lou J, Seed RI, Cormier A, Wu S, Cheng Y, Murray L, Tsui P, Connor J, Herbst R, Govaerts C, Barker T, Cambier S, Yanagisawa H, Goodsell A, Hashimoto M, Brand OJ, Cheng R, Ma R, McKnelly KJ, Wen W, Hill A, Jablons D, Wolters P, Kitamura H, Araya J, Barczak AJ, Erle DJ, Reichardt LF, Marks JD, Baron JL, Nishimura SL.

Sci Transl Med. 2014 Jun 18;6(241):241ra79. doi: 10.1126/scitranslmed.3008074.

13.

Identifying blood-brain-barrier selective single-chain antibody fragments.

Jones AR, Stutz CC, Zhou Y, Marks JD, Shusta EV.

Biotechnol J. 2014 May;9(5):664-74. doi: 10.1002/biot.201300550. Epub 2014 Mar 18.

14.

Identification of the synaptic vesicle glycoprotein 2 receptor binding site in botulinum neurotoxin A.

Strotmeier J, Mahrhold S, Krez N, Janzen C, Lou J, Marks JD, Binz T, Rummel A.

FEBS Lett. 2014 Apr 2;588(7):1087-93. doi: 10.1016/j.febslet.2014.02.034. Epub 2014 Feb 25.

15.

RNA aptasensor for rapid detection of natively folded type A botulinum neurotoxin.

Janardhanan P, Mello CM, Singh BR, Lou J, Marks JD, Cai S.

Talanta. 2013 Dec 15;117:273-80. doi: 10.1016/j.talanta.2013.09.012. Epub 2013 Sep 13.

16.

Sirtuin 3 deficiency does not augment hypoxia-induced pulmonary hypertension.

Waypa GB, Osborne SW, Marks JD, Berkelhamer SK, Kondapalli J, Schumacker PT.

Am J Respir Cell Mol Biol. 2013 Dec;49(6):885-91. doi: 10.1165/rcmb.2013-0191OC.

17.

Peroxiredoxin-5 targeted to the mitochondrial intermembrane space attenuates hypoxia-induced reactive oxygen species signalling.

Sabharwal SS, Waypa GB, Marks JD, Schumacker PT.

Biochem J. 2013 Dec 15;456(3):337-46. doi: 10.1042/BJ20130740.

18.
19.

Identification of the SV2 protein receptor-binding site of botulinum neurotoxin type E.

Mahrhold S, Strotmeier J, Garcia-Rodriguez C, Lou J, Marks JD, Rummel A, Binz T.

Biochem J. 2013 Jul 1;453(1):37-47. doi: 10.1042/BJ20130391.

PMID:
23621114
20.

Use of a new functional dual coating (FDC) assay to measure low toxin levels in serum and food samples following an outbreak of human botulism.

Jones RG, Marks JD.

J Med Microbiol. 2013 Jun;62(Pt 6):828-35. doi: 10.1099/jmm.0.053124-0. Epub 2013 Mar 21.

PMID:
23518650
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk